Evidence map›Paper›PMID 29333579›Full record

ArticleInternational urology and nephrology2018

Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center.

J L H Ruud Bosch, Francis Vekeman, Mei Sheng Duh, Maureen Neary, Matthew Magestro, Jonathan Fortier, Paul Karner, Raluca Ionescu-Ittu, Bernard A Zonnenberg

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 4 countries.

J L H Ruud BoschDepartment of Urology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, Netherlands.
Francis VekemanGroupe d'analyse, Ltée, 1000 De La Gauchetiere West, Suite 1200, Montréal, QC, H3B 4W5, Canada.
Mei Sheng DuhAnalysis Group, Inc., 111 Huntington Avenue 14th Floor, Boston, MA, 02199, USA.
Maureen NearyNovartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA.
Matthew MagestroNovartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA.
Jonathan FortierGroupe d'analyse, Ltée, 1000 De La Gauchetiere West, Suite 1200, Montréal, QC, H3B 4W5, Canada.
Paul KarnerAnalysis Group, Inc., 111 Huntington Avenue 14th Floor, Boston, MA, 02199, USA.
Raluca Ionescu-IttuGroupe d'analyse, Ltée, 1000 De La Gauchetiere West, Suite 1200, Montréal, QC, H3B 4W5, Canada.
Bernard A ZonnenbergDepartment of Internal Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, Netherlands. B.Zonnenberg@kpnmail.nl.ORCID http://orcid.org/0000-0003-0103-1979
Group for Research in Decision Analysis · CAAnalysis Group (United States) · USHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the patient characteristics, treatments, disease monitoring, and kidney function of patients with sporadic angiomyolipoma (sAML), stratified by the number and size of renal angiomyolipomas (AMLs).

methodsSingle-center retrospective analysis of patients with sAML treated from 1990 to 2015 in a dedicated clinic for inheritable tumor syndromes in a tertiary referral center from the Netherlands. Patients' first AML assessment at the clinic was defined as the index date. Patient characteristics were measured at the index date. Treatments, disease monitoring, and kidney function were measured post-index date.

resultsThe study sample included 53 patients followed for a total of 184.6 patient-years. At the index date, the largest AML was ≥ 3.5 cm for 26 patients and < 3.5 cm for 27 patients (including six patients with five or more AMLs of < 3.5 cm). As compared to patients with AMLs < 3.5 cm, patients with largest AML ≥ 3.5 cm had higher frequency of pre-index bleeding episodes (31 vs. 4%), pre-index hypertension (35 vs. 15%), post-index nephrectomy (19 vs. 4%), post-index embolization (8 vs. 0%), and post-index renal scans (1.14 vs. 0.74 scans/year). Kidney impairment was especially pronounced in young adults with AML ≥ 3.5 cm. On average, patients with sAML developed chronic kidney disease stage two earlier than the general Dutch population (age 42 vs. 55 years), but later than the patients with tuberous sclerosis complex (35 years).

conclusionsPatients with sAML, especially those with larger AMLs, have high disease burden.

Indexed as

AdultAgedAge FactorsAngiomyolipomaEmbolization, TherapeuticFemaleGlomerular Filtration RateHemorrhageHumansHypertensionKidney NeoplasmsMaleMiddle AgedNeoplasms, Multiple PrimaryNephrectomyNetherlandsAngiomyolipomaDisease monitoringKidney functionTreatment

Identifiers

PMID29333579
PMCPMC5845070
OpenAlexW2784133366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.